{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:35:00Z","timestamp":1792704900385,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Germline mutations in signal transducer and activator of transcription 1 (STAT1), which lead to primary immunodeficiency, are classified as defects in intrinsic and innate immunity. To date, no comprehensive overview comparing GOF with LOF in early-onset immunodeficiency has been compiled.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To collect and systematically review all studies reporting STAT1 GOF and LOF cases, and to describe the clinical, diagnostic, molecular, and therapeutic characteristics of all the conditions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A systematic review of the PubMed, EMBASE, Web of Science, Scopus, and Cochrane to identify articles published before May 23, 2020. Data pertaining to patients with a genetic diagnosis of STAT1 GOF or LOF germline mutations, along with detailed clinical data, were reviewed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The search identified 108 publications describing 442 unique patients with STAT1 GOF mutations. The patients documented with chronic mucocutaneous candidiasis (CMC; 410\/442), lower respiratory tract infections (210\/442), and autoimmune thyroid disease (102\/442). Th17 cytopenia was identified in 87.8% of those with GOF mutations. Twenty-five patients with GOF mutations received hematopoietic stem cell transplantation (HSCT), and 10 died several months later. Twelve of 20 patients who received JAK inhibitor therapy showed improved symptoms. Twenty-one publications described 39 unique patients with STAT1 LOF mutations. The most common manifestations were Mendelian susceptibility to mycobacterial diseases (MSMD) (29\/39), followed by osteomyelitis (16\/39), and lymphadenopathy (9\/39). Missense, indel, and frameshift mutations were identified as LOF mutations. There were no obvious defects in lymphocyte subsets or immunoglobulin levels. Eighteen patients required antimycobacterial treatment. Three patients received HSCT, and one of the three died from fulminant EBV infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    STAT1 GOF syndrome is a clinical entity to consider when confronted with a patient with early-onset CMC, bacterial respiratory tract infections, or autoimmune thyroid disease as well as Th17 cytopenia and humoral immunodeficiency. HSCT is still not a reasonable therapeutic choice. Immunoglobulin replacement therapy and JAK inhibitors are an attractive alternative. STAT1 LOF deficiency is a more complicated underlying cause of early-onset MSMD, osteomyelitis, respiratory tract infections, and Herpesviridae infection. Anti-mycobacterial treatment is the main therapeutic choice. More trials are needed to assess the utility of HSCT.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.654406","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:38:53Z","timestamp":1615423133000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity."},{"key":"B2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B3","first-page":"1","article-title":"Transcription protein STAT1: biology and relation to cancer","volume":"53","author":"Ad\u00e1mkov\u00e1","year":"2007","journal-title":"Folia Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1126\/science.1061154","article-title":"Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation","volume":"293","author":"Dupuis","year":"2001","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1100102","article-title":"STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis","volume":"365","author":"van de Veerdonk","year":"2011","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1189\/jlb.5RI0516-237RR","article-title":"STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases","volume":"101","author":"Lorenzini","year":"2017","journal-title":"J Leukoc Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s10875-019-00687-4","article-title":"Novel gain-of-function mutation in Stat1 sumoylation site leads to CMC\/CID phenotype responsive to ruxolitinib","volume":"39","author":"Al Shehri","year":"2019","journal-title":"J Clin Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12185-020-02860-7","article-title":"Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation","volume":"112","author":"Moriya","year":"2020","journal-title":"Int J Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/ng1097","article-title":"Impaired response to interferon-alpha\/beta and lethal viral disease in human STAT1 deficiency","volume":"33","author":"Dupuis","year":"2003","journal-title":"Nat Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.4049\/jimmunol.176.8.5078","article-title":"Human complete Stat-1 deficiency is associated with defective type I and IIIFN responses in vitro but immunity to some low virulence viruses in vivo","volume":"176","author":"Chapgier","year":"2006","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood-2011-01-330571","article-title":"Severe impairment of IFN-gamma and IFN-alpha responses in cells of a patient with a novel STAT1 splicing mutation","volume":"118","author":"Vairo","year":"2011","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jaip.2016.02.015","article-title":"A novel presentation of homozygous loss-of-function STAT-1 mutation in an infant with hyperinflammation-A case report and review of the literature","volume":"4","author":"Burns","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14785\/lpsn-2015-0013","article-title":"Autosomal dominant transmission of signal transduction and activator of transcription 1 (STAT1) mutation (Thr385Met) and extended lifespan","volume":"3","author":"Wessell","year":"2016","journal-title":"LymphoSign J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/pde.14011","article-title":"STAT1 gain-of-function and chronic demodicosis","volume":"37","author":"Molho-Pessach","year":"2020","journal-title":"Pediatr Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1111\/jdv.14413","article-title":"Rosacea and demodicidosis associated with gain-of-function mutation in STAT1","volume":"31","author":"Second","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1111\/jdv.16241","article-title":"Rosacea as a striking feature in family members with a STAT1 gain-of-function mutation","volume":"34","author":"S\u00e1ez-de-Ocariz","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jaci.2017.07.027","article-title":"Novel signal transducer and activator of transcription 1 mutation disrupts small ubiquitin-related modifier conjugation causing gain of function","volume":"141","author":"Sampaio","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","article-title":"Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome","volume":"131","author":"Uzel","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1474-4422(11)70109-0","article-title":"Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis","volume":"10","author":"Vlak","year":"2011","journal-title":"Lancet Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3389\/fimmu.2019.00768","article-title":"Impaired STAT3-dependent upregulation of IL2R\u03b1 in B cells of a patient with a STAT1 gain-of-function mutation","volume":"10","author":"van Zelm","year":"2019","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10875-018-0513-z","article-title":"Aortic calcification in a patient with a gain-of-function STAT1 mutation","volume":"38","author":"Smyth","year":"2018","journal-title":"J Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e234120","DOI":"10.1136\/bcr-2019-234120","article-title":"Cryptococcal pneumonia in an adolescent with a gain-of-function variant in signal transduction and activator of transcription 1 (STAT1)","volume":"13","author":"Marinelli","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10875-018-0554-3","article-title":"Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency","volume":"38","author":"Hartono","year":"2018","journal-title":"J Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/01.inf.0000437067.43859.4c","article-title":"Mycobacterium szulgai chronic multifocal osteomyelitis in an adolescent with inherited STAT1 deficiency","volume":"32","author":"Shamriz","year":"2013","journal-title":"Pediatr Infect Dis J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/humu.22113","article-title":"Dominant-negative STAT1 SH2 domain mutations in unrelated patients with mendelian susceptibility to mycobacterial disease","volume":"33","author":"Tsumura","year":"2012","journal-title":"Hum Mutat."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1182\/blood-2010-04-280586","article-title":"A novel form of human STAT1 deficiency impairing early but not late responses to interferons","volume":"116","author":"Kong","year":"2010","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jaci.2016.09.035","article-title":"Alanine-scanning mutagenesis of human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variants","volume":"140","author":"Kagawa","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1172\/JCI37083","article-title":"A partial form of recessive STAT1 deficiency in humans","volume":"119","author":"Chapgier","year":"2009","journal-title":"J Clin Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/INF.0b013e3181fdff4a","article-title":"The clinical spectrum of patients with deficiency of signal transducer and activator of transcription-1","volume":"30","author":"Averbuch","year":"2011","journal-title":"Pediatr Infect Dis J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1371\/journal.pgen.0020131","article-title":"Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease","volume":"2","author":"Chapgier","year":"2006","journal-title":"PLoS Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.smim.2014.09.008","article-title":"Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity","volume":"26","author":"Bustamante","year":"2014","journal-title":"Semin Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10875-019-00672-x","article-title":"current status of the management of mendelian susceptibility to mycobacterial disease in mainland China","volume":"39","author":"Ying","year":"2019","journal-title":"J Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1159\/000493455","article-title":"Anti-IFN-\u03b3 antibody promotes osteoclastogenesis in human bone marrow monocyte-derived macrophages co-cultured with tuberculosis-activated Th1 cells","volume":"49","author":"Deng","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/cid\/ciw020","article-title":"Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation","volume":"62","author":"Mossner","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"ofx202","DOI":"10.1093\/ofid\/ofx202","article-title":"Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease","volume":"4","author":"Zimmerman","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.654406\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:38:56Z","timestamp":1615423136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.654406\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2021.654406"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.654406","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"article-number":"654406"}}